Table 4.

The discrimination performance of models predicting the survival from a combined event at 10 years postbiopsy

Patient Group and ModelcNRI
All patients
 Baseline model (without crescents): initial eGFR; time-averaged MAP and proteinuria; and M, E, S, T (0 versus 1–2)
 Baseline model and any crescents0.142 (−0.019; 0.222); P=0.08
 Baseline model and no, less than one sixth, and greater than or equal to one sixth crescents0.132 (−0.085; 0.216); P=0.16
 Baseline model and no, less than one fourth, and greater than or equal to one fourth crescents0.111 (−0.131; 0.210); P=0.24
Patients with no immunosuppression
 Baseline model (without crescents): initial eGFR; time-averaged MAP and proteinuria; and M, E, S, T (0 versus 1–2)
 Baseline model and any crescents0.200 (0.053; 0.281); P=0.02
 Baseline model and no, less than one sixth, and greater than or equal to one sixth crescents0.191 (0.000; 0.276); P=0.05
 Baseline model and no, less than one fourth, and greater than or equal to one fourth crescents0.205 (0.007; 0.285); P=0.04
Patients with any immunosuppression
 Baseline model (without crescents): initial eGFR; time-averaged MAP and proteinuria; and M, E, S, T (0 versus 1–2)
 Baseline model and any crescents0.037 (−0.410; 0.591); P=0.78
 Baseline model and no, less than one sixth, and greater than or equal to one sixth crescents0.030 (−0.505; 0.617); P=0.58
 Baseline model and no, less than one fourth, and greater than or equal to one fourth crescents0.056 (−0.550; 0.749); P=0.66
  • Results are presented as continuous net reclassification improvement (cNRI) with 95% confidence interval in parentheses. cNRI values significantly greater than zero suggest improvement in discrimination by adding crescents to the model.